Document is current
Any future updates will be listed below
-
Authors
Zavvar, Taraneh Sadat
Hörmann, Anton Amadeus
Konijnenberg, Mark
Kraihammer, Martin
Mair, Christian
Kronthaler, Ariane
Joosten, Lieke
Laverman, Peter
Gruber, Leonhard
di Santo, Gianpaolo
Decristoforo, Clemens
Virgolini, Irene
von Guggenberg, Elisabeth
-
Funding
Funding for this research was provided by:
Austrian Science Fund (FWF DOC 110 doc.funds)
University of Innsbruck and Medical University of Innsbruck
- License Information
-
More Information
Article History
Received: 16 August 2024
Accepted: 1 November 2024
First Online: 7 December 2024
Declarations
:
: All animal experiments were approved by the Austrian Ministry of Science (2022–0.351.553) or by the Dutch animal ethics committee (CCD) of the Radboud University and the Nijmegen Medical Centre animal ethics committee (RUDEC) (2020–0007–020). The first dosimetry study in a patient with SCLC was conducted on a named-patient basis.
: Written informed consent was obtained from the patient in accordance with the Declaration of Helsinki.
: The patient has provided consent for the publication of the data included in this article.
: EG and AH are listed as an inventor on the European patent application no. 17174973. EG consults Evergreen Theragnostics, Inc. in product development. No other conflict of interest relevant to this article was reported.
: Not applicable.
